The result showed that the genes (including CD276, CD274, and PDCD1LG2) had functions on T-cell co-inhibition contributing to tumor cell evasion were enriched in high-risk groups and become important targets for blockade-based immunotherapy in cancer (Figure 5B, Supplementary Figure S9); (Lee et al., 2017; Yearley et al., 2017; Wang et al., 2019). The gene discussed is CD274; the disease is neoplasm.